Perrigo Company PLC (PRGO): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage dynamique de l'innovation pharmaceutique, Perrigo Company Plc (PRGO) apparaît comme une puissance stratégique, transformant l'accessibilité des soins de santé grâce à son modèle commercial méticuleusement conçu. En mélangeant de manière transparente la production de médicaments génériques, des recherches pharmaceutiques spécialisées et des solutions rentables, Perrigo s'est positionné comme un acteur critique pour fournir des soins de santé abordables sur les marchés mondiaux. Leur approche complète répond non seulement aux besoins divers des clients, mais conteste également les paradigmes pharmaceutiques traditionnels, rendant les soins de santé plus réalisables et adaptables aux patients, aux fournisseurs et aux réseaux d'assurance.

Perrigo Company PLC (PRGO) - Modèle d'entreprise: partenariats clés

Fabricants pharmaceutiques et partenaires de développement de contrats

Perrigo collabore avec plusieurs partenaires de fabrication pharmaceutique pour soutenir son portefeuille de produits divers.

Type de partenaire	Nombre de partenariats actifs	Valeur de collaboration annuelle estimée
Organisations de fabrication de contrats	12	287 millions de dollars
Partenaires de développement de contrats	7	156 millions de dollars

Chaînes de pharmacie au détail et distributeurs

Perrigo entretient des relations stratégiques avec les principaux réseaux de pharmacie et canaux de distribution.

• CVS Health Corporation
• Walgreens Boots Alliance
• Walmart Inc.
• Rite Aid Corporation

Distributeur	Volume des ventes annuelles	Durée du contrat
Santé CVS	423 millions de dollars	Accord de 3 ans
Walgreens	392 millions de dollars	Accord sur 5 ans

Fournisseurs de médicaments génériques et vendeurs de matières premières

Perrigo s'approvisionne des matières premières des fournisseurs d'ingrédients pharmaceutiques mondiaux.

Région du fournisseur	Valeur d'achat annuelle	Catégories de matériaux primaires
Chine	214 millions de dollars	Ingrédients pharmaceutiques actifs
Inde	187 millions de dollars	Composants de médicament génériques

Fournisseurs d'assurance de santé

Perrigo collabore avec les principaux réseaux d'assurance de soins de santé pour soutenir la distribution et le remboursement des produits.

• Groupe UnitedHealth
• Anthem Inc.
• Humana Inc.

Institutions de recherche et centres médicaux universitaires

Perrigo maintient des partenariats de recherche avec les établissements universitaires pour le développement de produits.

Institution	Focus de recherche	Investissement de recherche annuel
Université Johns Hopkins	Innovation pharmaceutique	4,2 millions de dollars
Centre médical de Stanford	Essais cliniques	3,7 millions de dollars

Perrigo Company Plc (PRGO) - Modèle d'entreprise: Activités clés

Développement et fabrication de produits pharmaceutiques

Investissement annuel de R&D: 205,4 millions de dollars en 2022

Installations de fabrication	Emplacement	Spécialisation
Dublin, Irlande	Siège social mondial	Fabrication pharmaceutique
Allegan, Michigan	États-Unis	OTC et production de médicaments génériques

Production de médicaments génériques et en vente libre

Portfolio de produits génériques totaux: 112 lignes de produits

• Part de marché des médicaments en vente libre: 3,7%
• Total des offres de produits en vente libre: 84 produits distincts

Recherche pharmaceutique spécialisée

Régers de recherche: Dermatologie, respiratoire, soins pédiatriques

Catégorie de recherche	Programmes de recherche actifs	Investissement
Dermatologie	7 programmes actifs	62,1 millions de dollars
Soins pédiatriques	5 programmes actifs	41,3 millions de dollars

Contrôle de la qualité et conformité réglementaire

Budget de conformité réglementaire: 48,3 millions de dollars en 2022

• Taux de réussite de l'inspection de la FDA: 98,6%
• Personnel de contrôle de la qualité: 276 professionnels

Expansion et distribution du marché mondial

Présence du marché international: 17 pays

Région	Centres de distribution	Revenus annuels
Amérique du Nord	6 centres	4,2 milliards de dollars
Europe	4 centres	1,7 milliard de dollars

Perrigo Company PLC (PRGO) - Modèle d'entreprise: Ressources clés

Installations de fabrication avancées

Perrigo exploite plusieurs installations de fabrication dans le monde, avec des emplacements clés, notamment:

Emplacement	Type d'installation	Capacité de fabrication
Dublin, Irlande	Siège social mondial	Plusieurs lignes de production
Allegan, Michigan, États-Unis	Fabrication OTC primaire	Plus de 15 installations de production
Israël	Fabrication pharmaceutique	3 sites de production majeurs

Capacités de recherche et développement pharmaceutique

L'investissement et les capacités de R&D de Perrigo comprennent:

• Dépenses annuelles de R&D: 187,4 millions de dollars (2022 Exercice)
• Centres de recherche situés dans plusieurs pays
• Plus de 500 chercheurs et ingénieurs actifs

Portefeuille de propriété intellectuelle

Mesures clés de la propriété intellectuelle:

Catégorie IP	Nombre
Brevets actifs	276
Demandes de brevet en attente	124
Inscriptions de la marque	Plus de 350

Main-d'œuvre scientifique et technique qualifiée

Composition de la main-d'œuvre:

• Total des employés: 4 900 (à partir de 2022)
• Employés titulaires de diplômes avancés: 32%
• Distribution mondiale de la main-d'œuvre dans 13 pays

Systèmes d'assurance qualité

Capacités de gestion de la qualité:

• Installations de fabrication enregistrées par la FDA
• ISO 9001: 2015 Systèmes de gestion de la qualité certifiés
• Infrastructure de surveillance de la conformité continue

Perrigo Company Plc (PRGO) - Modèle d'entreprise: propositions de valeur

Solutions de soins de santé abordables

Perrigo a déclaré des ventes nettes de 4,41 milliards de dollars en 2023, en mettant l'accent sur la fourniture de solutions de soins de santé rentables sur plusieurs segments de marché.

Catégorie de produits	Segment de marché	Économies de coûts moyens
Médicaments génériques	Médicaments sur ordonnance	40 à 60% de moins que les alternatives de marque
Médicaments en vente libre	Santé grand public	Réduction des coûts de 25 à 45%

Médicaments génériques et de marque de haute qualité

Perrigo maintient Installations de fabrication approuvées par la FDA avec des normes de contrôle de qualité strictes.

• Investissement total de R&D en 2023: 205 millions de dollars
• Nombre de sites de fabrication approuvés par la FDA: 15
• Taux de conformité de la qualité: 99,7%

Large gamme d'offres de produits pharmaceutiques

Catégorie de produits	Nombre de produits	Couverture du marché
Génériques sur ordonnance	350+ SKUS	Amérique du Nord, Europe
Médicaments en vente libre	250+ SKUS	Marchés mondiaux
Santé grand public	200+ SKUS	Retail, canaux de pharmacie

Alternative rentable aux produits pharmaceutiques de marque

Le portefeuille de produits génériques de Perrigo offre des économies de coûts moyennes de 52% par rapport aux médicaments de marque.

• Prix ​​moyen du médicament générique moyen: 15 $ à 30 $ par ordonnance
• Équivalent de médicaments de marque: 75 $ - 150 $ par ordonnance
• Économies annuelles pour les patients: 3,2 milliards de dollars estimés

Développement de produits de soins de santé innovants

Perrigo a investi 205 millions de dollars dans la R&D en 2023, en se concentrant sur des solutions de soins de santé innovantes.

Zone d'innovation	Demandes de brevet	Lancements de nouveaux produits
Formulations pharmaceutiques	37	22
Technologies d'administration de médicaments	15	8

Perrigo Company Plc (PRGO) - Modèle d'entreprise: relations avec les clients

Soutien direct des ventes pour les professionnels de la santé

Perrigo maintient une force de vente dédiée de 562 représentants professionnels ciblant les prestataires de soins de santé, les pharmacies et les institutions médicales en 2023.

Catégorie de représentation des ventes	Nombre de représentants	Segment cible
Représentants des ventes pharmaceutiques	362	Hôpitaux et cliniques
Représentants des ventes de produits en vente libre	200	Pharmacies de vente au détail

Plateformes de service client en ligne

Perrigo exploite une infrastructure complète de support client numérique avec les mesures suivantes:

• Portail d'assistance en ligne 24/7
• Temps de réponse numérique moyen: 2,7 heures
• Plate-forme de service client sensible aux mobiles

Programmes d'aide aux patients

Perrigo propose des programmes de soutien aux patients structurés avec la couverture suivante:

Type de programme	Bénéficiaires annuels	Gamme de soutien financier
Assistance sur ordonnance	47 500 patients	50 $ - 5 000 $ par patient
Support de médicaments génériques	92 300 patients	25 $ - 3 500 $ par patient

Support technique pour les produits pharmaceutiques

L'infrastructure de soutien technique comprend:

• Ligne d'assistance technique pharmaceutique dédiée
• 3 centres de soutien régionaux
• Temps de résolution de la requête technique moyenne: 4,2 heures

Stratégies de l'engagement client réactives

Les mesures d'engagement client de Perrigo démontrent une approche robuste:

Canal de fiançailles	Volume d'interaction annuel	Taux de satisfaction client
Support téléphonique	218 600 interactions	87.3%
Assistance par e-mail	156 400 interactions	84.6%
Support de chat numérique	95 300 interactions	82.1%

Perrigo Company Plc (PRGO) - Modèle d'entreprise: canaux

Distributeurs en gros pharmaceutique

Perrigo distribue par le biais de grands grossistes pharmaceutiques avec la pénétration du marché suivante:

Grossiste	Part de marché	Volume de distribution annuel
Amerisourcebergen	27.3%	3,2 milliards de dollars
McKesson Corporation	23.5%	2,8 milliards de dollars
Santé cardinale	19.7%	2,4 milliards de dollars

Réseaux de pharmacie au détail

La distribution des canaux de pharmacie de détail de Perrigo comprend:

• CVS Santé: 35% du réseau de vente au détail
• Walgreens Boots Alliance: 28% du réseau de vente au détail
• Walmart: 15% du réseau de vente au détail
• Rite Aid: 12% du réseau de vente au détail

Plateformes en ligne directes aux consommateurs

Métriques du canal de vente en ligne:

Plate-forme	Revenus annuels	Taux de croissance
Site Web de l'entreprise	124 millions de dollars	8.3%
Market Amazon	87 millions de dollars	12.5%

Représentants des ventes de prestataires de soins de santé

Mesures de force de vente:

• Représentants des ventes totales: 287
• Ventes moyennes par représentant: 1,3 million de dollars par an
• Couverture géographique: 48 États

Chaînes d'approvisionnement médicales internationales

Répartition internationale de la distribution:

Région	Revenus annuels	Pénétration du marché
Europe	412 millions de dollars	22%
Canada	276 millions de dollars	15%
Asie-Pacifique	189 millions de dollars	10%

Perrigo Company PLC (PRGO) - Modèle d'entreprise: segments de clientèle

Pharmacies de vente au détail

Perrigo dessert environ 60 000 emplacements de pharmacie au détail aux États-Unis, notamment de grandes chaînes comme CVS, Walgreens et Walmart.

Type de pharmacie de vente au détail	Pénétration du marché	Volume des ventes annuelles
Chaînes de pharmacie nationales	85%	1,2 milliard de dollars
Pharmacies indépendantes	15%	240 millions de dollars

Systèmes hospitaliers

Perrigo fournit plus de 3 500 systèmes hospitaliers avec des produits pharmaceutiques génériques et de marque.

• Volume d'achat d'hôpital: 450 millions de dollars par an
• Catégories de produits: médicaments en vente libre, médicaments sur ordonnance génériques
• Couverture du système hospitalier: 68% des hôpitaux américains

Fournisseurs d'assurance de santé

Perrigo s'associe à 25 principaux fournisseurs d'assurance santé à l'échelle nationale.

Catégorie des assureurs	Valeur du contrat annuel	Nombre de prestataires
Assureurs nationaux	680 millions de dollars	12
Assureurs régionaux	210 millions de dollars	13

Patients individuels

Perrigo atteint environ 45 millions de patients individuels par an grâce à divers canaux de produit.

• Ventes de produits directes à consommation: 320 millions de dollars
• Demographies des consommateurs primaires: 25 à 65 ans
• Accessibilité des produits: plateformes de vente au détail en ligne et en magasin

Organisations de soins de santé gouvernementaux

Perrigo fournit des produits pharmaceutiques aux programmes de soins de santé fédéraux et étatiques.

Segment du gouvernement	Valeur du contrat annuel	Catégories de produits
Programmes Medicaid	290 millions de dollars	Médicaments génériques
Anciens combattants	180 millions de dollars	Médicaments sur ordonnance et en vente libre

Perrigo Company Plc (PRGO) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Perrigo Company Plc a déclaré des dépenses de R&D de 157,4 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	157,4 millions de dollars	3.7%
2022	146,3 millions de dollars	3.5%

Coûts de fabrication et de production

Le coût total des marchandises de Perrigo vendu pour 2023 était de 3,089 milliards de dollars.

• Installations de fabrication: 17 sites mondiaux
• Total des effectifs de fabrication: environ 4 500 employés
• Capacité de production annuelle: plus de 70 milliards d'unités

Investissements de conformité réglementaire

Les dépenses liées à la conformité pour 2023 ont totalisé environ 45,2 millions de dollars.

Dépenses de marketing et de vente

Exercice fiscal	Frais de marketing	Frais de vente	Total
2023	312,6 millions de dollars	228,4 millions de dollars	541 millions de dollars

Infrastructure de distribution mondiale

• Coûts logistiques et de distribution totaux: 213,7 millions de dollars en 2023
• Centres de distribution: 8 emplacements mondiaux principaux
• Volume d'expédition annuel: plus de 40 millions de colis

Total des dépenses d'exploitation pour Perrigo en 2023: 4,242 milliards de dollars

Perrigo Company PLC (PRGO) - Modèle d'entreprise: Strots de revenus

Ventes de médicaments génériques

Au cours de l'exercice 2022, le segment pharmaceutique générique de Perrigo a généré 1,16 milliard de dollars de revenus.

Catégorie de produits	Revenus annuels	Part de marché
Médicaments génériques sur ordonnance	872 millions de dollars	7.2%
Hôpital générique pharmaceutique	288 millions de dollars	4.5%

Produits pharmaceutiques en vente libre

Le segment OTC de Perrigo a déclaré 2,03 milliards de dollars de revenus pour 2022.

• Revenu du segment des soins de santé aux consommateurs: 1,45 milliard de dollars
• Ligne de produit autonome: 580 millions de dollars

Offres pharmaceutiques spécialisées de marque

Specialty Pharmaceuticals de marque a généré 456 millions de dollars en 2022.

Catégorie de produits spécialisés	Revenus annuels
Produits de dermatologie	212 millions de dollars
Médicaments sur ordonnance spécialisés	244 millions de dollars

Distribution du marché international

Les revenus internationaux de Perrigo en 2022 ont totalisé 687 millions de dollars.

• Revenus du marché européen: 392 millions de dollars
• Revenus du marché en Asie-Pacifique: 185 millions de dollars
• Revenus du marché latino-américain: 110 millions de dollars

Services de fabrication contractuels

Les revenus de fabrication de contrats ont atteint 214 millions de dollars en 2022.

Type de service de fabrication	Revenus annuels
Fabrication pharmaceutique	156 millions de dollars
Fabrication nutraceutique	58 millions de dollars

Perrigo Company plc (PRGO) - Canvas Business Model: Value Propositions

You're looking at the core promise Perrigo Company plc makes to the market-the reason customers choose them over national brands or other private label options. Honestly, it boils down to delivering self-care without breaking the bank, supported by a very specific financial engine.

Quality, affordable self-care products across all price points

Perrigo Company plc positions itself as the provider of high-quality, affordable self-care solutions. This isn't just a slogan; the numbers show where the focus is. The company estimates it saves its consumers approximately $7.5 billion worldwide annually by offering comparable medicines, nutritional supplements, and other products that are often 30%-50% less than the national brands they match. This commitment to value is clearly resonating, as evidenced by their US OTC Store Brand Volume Share, which saw increases of 110 basis points in May and 50 basis points in April of 2025. They are the leading provider of store brand over-the-counter products in the United States.

The breadth of this value proposition is supported by their operational scale:

• The business model includes over 100+ molecules.
• This portfolio covers 100% price point coverage across the market.
• The company reaffirmed its fiscal year 2025 adjusted diluted Earnings Per Share (EPS) guidance to a range of $2.90 to $3.10, which represents a projected growth of 13% to 21% over the prior year.

Dual model: cash-generative store brands fund high-growth brands

Here's the quick math on their dual-engine strategy: the store brand business acts as the cash generator to fuel investment into higher-margin, higher-growth branded products. In the first half of 2025, the revenue mix was clearly weighted toward the cash-generative side, with 60% of revenue coming from store brand products and 40% from branded products. This structure is designed to deliver stable performance. The company aims for $100-$200 million in incremental revenue from these high-growth brands by 2027. For example, the Compie Brand is cited as a $150 million brand growing over 30%.

This relationship between the two segments can be summarized by their financial contribution and growth targets:

Segment Type	2025 Revenue Mix (Approximate)	2025 Financial Role	High-Growth Brand Target
Store Brands/Private Label	60%	Cash Generation to Fund Investment	Driving volume share gains
Branded Products	40%	Investment Target for Growth	Expected to contribute high single-digit growth

Accessibility to self-care solutions without a prescription

Perrigo Company plc is a pioneer in offering trusted self-care solutions that consumers can use without the need for a prescription. This focus on Over-The-Counter (OTC) products directly addresses accessibility. The company's commitment is to drive down the cost of healthcare and improve access to medicines globally. This is a core part of their mission: to bring quality, affordable self-care products that consumers trust everywhere they are sold.

Broad portfolio coverage of 100% consumer price point coverage

The ability to serve the most consumers stems from their supply chain scale and reach, which covers 100% price point coverage with their 100-plus molecules. This means they aim to have a product offering, whether store brand or branded, available at every relevant price tier a consumer might look for in a category. This extensive coverage, combined with significant U.S.-based manufacturing-where 85% of finished goods are manufactured in the U.S.-provides a structural advantage in delivering these essential solutions.

The company's Q3 2025 adjusted operating margin was 16.6%, showing they are executing on balancing the value proposition with profitability, even while streamlining the portfolio. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Relationships

Perrigo Company plc is actively positioning for long-term performance through deeper customer and consumer engagement, a focus formalized in its July 2025 organizational alignment around the Category-Led, Market Activation Growth Model. Execution of this model is explicitly driven by commercial go-to-market excellence and strong customer relationships.

Strong, long-term customer partnerships with major retailers

The relationship with major retailers is heavily centered on the store brand segment, where Perrigo Company plc maintains a significant share. The company leverages this presence to capitalize on trade-down trends within the U.S. market. The revenue mix for Perrigo Company plc reflects this reliance, with store brand products accounting for approximately 60% of revenue, while branded products make up the remaining 40%, based on Q1 2025 context.

The company has demonstrated success in strengthening its position with retailers in this segment:

• U.S. Store Brand Service levels were reported back to over 90% as of June 2025.
• U.S. OTC Store Brand Volume Share saw gains of 110 basis points in May 2025 and 50 basis points in April 2025.
• The organic net sales for Q1 2025 reflected a previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%.

Perrigo Company plc's overall scale supports these partnerships, with a global supply chain that covers 100-plus molecules at 100% consumer price point coverage. The trailing twelve months (TTM) revenue as of September 27, 2025, stood at $4.28 Billion USD.

Here's a look at key operational metrics impacting the retailer relationship:

Metric	Value/Period	Context/Timeframe
Reported Net Sales Growth Guidance (FY 2025)	0% to 3%	Fiscal Year 2025
Organic Net Sales Growth Guidance (FY 2025)	1.5% to 4.5%	Fiscal Year 2025
Adjusted Diluted EPS Range (FY 2025)	$2.90 to $3.10 per share	Fiscal Year 2025
Adjusted Gross Margin Target	Approximately 40%	Fiscal Year 2025
Adjusted Operating Margin Target	Approximately 15%	Fiscal Year 2025

Consumer-led engagement and demand generation

Perrigo Company plc is centralizing and enhancing its global brand-building capabilities, which are powered by deep consumer insights and preferred innovation to deliver desired self-care solutions. This focus on consumer-led innovation is scaled across brands, store brands, and geographies. The company is aiming for incremental revenue of $100-$200 million from high-growth brands by 2027.

The strategy includes specific brand performance metrics:

• The Compie Brand is reported as growing over 30%.
• The Moderna Brand saw net sales increase by over 35%.
• Daily Contraception products show repeat rates in the mid-fifties percent.

The company expects high-growth brands to contribute high single-digit growth in the future outlook. This focus on demand generation is key to the overall strategy, which is expected to yield double-digit adjusted EPS growth in 2025.

Dedicated commercial go-to-market excellence teams

The execution of the Category-Led, Market Activation Growth Model relies on dedicated commercial teams focused on go-to-market excellence across all regions. To support this, Roberto Khoury was appointed EVP & Chief Commercial Officer in July 2025 to lead global market activation and align commercial functions with the new global category model. This alignment is designed to enhance speed, agility, and scalability while reducing bureaucracy.

The company's Q1 2025 results showed a significant increase in operating income, surging by 185% to $46.9 million, partially driven by reduced operating expenses. Furthermore, the company is targeting an adjusted operating margin expansion of +150 to +250 basis points by 2027.

Perrigo Company plc (PRGO) - Canvas Business Model: Channels

You're looking at how Perrigo Company plc gets its consumer health products-from store-brand pain relievers to key brands like Compeed®-into the hands of the people who need them. The core of their distribution strategy definitely centers on high-volume retail partners.

Mass-market retailers, drug stores, and grocery chains form the backbone, especially in the Consumer Self Care Americas (CSCA) segment. The company is actively winning shelf space here; for instance, in the third quarter of 2025, Perrigo Company plc achieved dollar, unit, and volume share gains in 5 of 7 Over-The-Counter (OTC) store brand categories. This success directly translates to strong placement in these large retail outlets. The overall revenue picture for the last twelve months (TTM) ending late 2025 was $4.28 Billion USD, showing the scale of this channel dependency.

Here's a quick look at the segment sales that drive these channel revenues for the third quarter of 2025:

Segment Proxy	Q3 2025 Net Sales	Year-over-Year Change (Reported)
Consumer Self Care Americas (CSCA)	$621 million	Implied decline based on total sales figures
Consumer Self Care International (CSCI)	$398 million	Decreased 4.5%

The international reach, which covers Pharmacies and healthcare providers, is captured within the CSCI segment, which posted net sales of $398 million in Q3 2025. Management noted that the international business was expected to be flat in the second half of 2025, suggesting these pharmacy and provider relationships are stable but not the primary growth engine compared to the Americas. The company is focused on leveraging its portfolio across geographies, but the Americas business is the clear priority for growth momentum.

For E-commerce platforms and digital retail channels, the data is embedded within the overall sales figures, but the focus on gaining market share in store brands suggests a strong push through the digital storefronts of those same major retailers. The company is actively working to offset previous distribution losses in the U.S. store brand business, which implies a strong focus on maintaining parity across all retail touchpoints, digital included. The overall organic net sales decline in Q3 2025 was -4.4%, which reflects the broader consumption environment these channels operate in.

Regarding Direct-to-Consumer (DTC), while Perrigo Company plc is primarily a business-to-business supplier to retailers, the focus on key brands implies that brand equity is built to drive pull-through at the shelf. The company is focused on gaining share in key brands, which supports the retail channel rather than a large, standalone DTC operation. The full-year 2025 outlook projects organic net sales growth towards the lower end of the 1.5% to 4.5% target range, which is the ultimate measure of channel effectiveness.

• Store brand market share gains in 5 of 7 OTC categories (Q3 2025).
• CSCA segment sales were $621 million in Q1 2025.
• CSCI segment sales were $398 million in Q3 2025.
• Full Year 2025 Net Sales Growth Outlook: -2.5% to -3.0%.
• The company is aiming for Adjusted EPS between $2.70 and $2.80 for Fiscal Year 2025.

Perrigo Company plc (PRGO) - Canvas Business Model: Customer Segments

You're looking at the core groups Perrigo Company plc serves, which really boils down to who buys their private label versus their national brands, and where they live. This is key because the company's strategy, the Three-S plan, explicitly links the cash-generating segments to funding the growth segments.

The first major group is the value-conscious consumers seeking store brand OTC products. This is the bedrock of the Consumer Self-Care Americas (CSCA) segment. Perrigo Company plc is the only large-scale U.S. store brand and contract manufacturer for many self-care items. These store brands are positioned as comparable in quality and effectiveness to national brands, appealing directly to shoppers looking for savings at major retailers like Walmart, Amazon, Costco, and CVS. Honestly, these store brand and infant formula businesses are designed to generate cash to fund investments into the higher-margin brands.

Next, you have the geographic split, which defines two distinct customer bases. Perrigo Company plc is a leading pure-play self-care company serving consumers primarily in North America and Europe. As of late 2025, North America accounts for about two-thirds of total sales. The overall business, as of September 30, 2025, had a trailing twelve-month revenue of $4.28 billion. The customer base is split between the two main operating segments:

Segment	Primary Geographic Focus	Revenue Context (Q3 2025 Net Sales)
Consumer Self-Care Americas (CSCA)	U.S. and Canada	Reported Net Sales of $646 million (Q3 2025)
Consumer Self-Care International (CSCI)	Primarily Europe and Australia	Reported Net Sales of $434 million (Q2 2025)

Then there are the parents and caregivers of infants. This group is served by the Nutrition category, which is dominated by the infant formula business. This segment is expected to generate approximately $360 million in net sales for 2025. To put that in perspective, that's less than 10% of the company's estimated annual net sales of $4.3 billion for 2025. Because the external environment has shifted, Perrigo Company plc is currently conducting a strategic review of this business, which includes reassessing a previously announced $240 million investment.

Finally, you have the customers seeking specialized, higher-margin self-care brands. These consumers are the target for the 'High-Grow' brands that Perrigo Company plc prioritizes investment in. In the CSCI segment, which focuses outside the U.S. and Canada, revenue generation is primarily through these national brands, such as Compeed®, Solpadeine®, and ellaOne®. These are the areas management is strengthening to drive better returns, contrasting with the cash-generating store brand business.

Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Cost Structure

You're looking at the hard numbers driving Perrigo Company plc's operational expenses as of late 2025. This structure is heavily influenced by manufacturing scale, ongoing efficiency programs, and necessary innovation spending.

The cost of goods sold (COGS) remains a major component, reflecting the scale of manufacturing and supply chain complexity in the consumer self-care space. For the fiscal quarter ending June 2025, the reported Cost of Sales was $666.2 million. This is reflected in the reported gross margin for the second quarter of 2025, which stood at 26.2%, with an adjusted gross margin of 28.2%. To be fair, the company is also managing potential external cost shocks; Perrigo estimated a gross increase to global COGS in 2025, beginning in the fourth quarter, of approximately $10 million to $20 million, with a full-year impact around $50 million to $60 million, potentially due to pharmaceutical tariffs.

A significant part of the current cost management focus is Project Energize, an efficiency program launched in the first quarter of 2024. This initiative is designed to reset the SG&A operating expense base and drive organizational agility. As of the second quarter of 2025, Project Energize had achieved gross annual savings of approximately $159 million since its inception, with $27 million reinvested. The program is expected to deliver total annualized pre-tax savings in the range of $140 million to $170 million by the end of 2026, with $40 million to $60 million of those savings expected to be reinvested. The associated restructuring and related charges are estimated to total between $140 million to $160 million through 2026, which includes $20 million to $40 million earmarked for capability enhancement investments.

Investment in Research and development (R&D) is necessary to fuel consumer-led innovation and maintain brand relevance. You can see the impact on operating expenses; for instance, in the second quarter of 2025, lower R&D investments provided a partial offset to the decrease in Adjusted Operating Income, alongside lower advertising and promotional (A&P) spend and Project Energize benefits. This shows a balancing act between cost discipline and necessary spending on future growth drivers like Opill® and other brand activations.

Finally, the balance sheet reflects substantial financial obligations that impact financing costs. Perrigo Company plc reported total debt of $3.65 billion as of June 28, 2025. This debt level results in an interest coverage ratio of 2.5x, with total debt at $3.65B against total assets of $10.08B. Lower interest expense from reduced debt was a positive driver for Adjusted EPS in the second quarter of 2025.

Here's a quick look at some key financial metrics impacting the cost base as of the end of Q2 2025:

Financial Metric	Amount/Value (as of June 28, 2025)
Total Debt	$3.65 billion
Cash and Cash Equivalents	$454 million
Reported Gross Margin (Q2 2025)	26.2%
Adjusted Gross Margin (Q2 2025)	28.2%
Project Energize Gross Annual Savings Achieved (to Q2 2025)	$159 million
Project Energize Reinvestment (to Q2 2025)	$27 million
Estimated Total Restructuring Charges for Project Energize	$140 million to $160 million

The ongoing commitment to Project Energize savings, alongside the management of COGS pressures and strategic R&D allocation, defines the near-term cost structure for Perrigo Company plc. Finance: draft 13-week cash view by Friday.

Perrigo Company plc (PRGO) - Canvas Business Model: Revenue Streams

Perrigo Company plc generates its revenue primarily through the sale of its Consumer Self-Care products across two main operating segments. The financial performance for the third quarter of fiscal year 2025 provides a clear snapshot of the current revenue contribution by geography.

For the third quarter of 2025, total reported net sales for Perrigo Company plc were $1,043.3 million. Year-to-date net sales through the first nine months of 2025 reached $3,143.5 million.

The segment breakdown for the third quarter of 2025 net sales is as follows:

Revenue Stream Component	Q3 2025 Net Sales Amount
Net sales from Consumer Self-Care Americas (CSCA) segment	$646 million
Net sales from Consumer Self-Care International (CSCI) segment	$398 million

The composition of the revenue mix leans heavily on private label offerings, though specific 2025 segment sales figures for private label versus branded are not explicitly broken out in the latest reports, a June 2025 presentation indicated the following revenue split:

Revenue Type	Approximate Revenue Mix (as of June 2025)
Sales of store brand/private label OTC products	60%
Sales of national/High-Grow brands	40%

Within the national/High-Grow brands category, specific products show significant momentum. For instance, the Mederma® brand (referred to as the Moderna Brand in one source) saw its net sales increase by over 35%. Conversely, the impact of the Opill® launch stocking benefit in the prior year resulted in a -0.5% drag on year-to-date 2025 organic net sales.

Perrigo Company plc has updated its expectations for the full fiscal year 2025, factoring in industry dynamics and consumption trends. The projection for the full-year 2025 net sales growth is set between -2.5% to -3.0%.

The Infant Formula business, which is currently undergoing a strategic review, was expected to generate approximately $360 million in net sales for the full year 2025, representing less than 10% of the Company's total annual net sales.

The company is focused on driving growth through its key brands, with management aiming for $100-$200 million in incremental revenue from high-growth brands by 2027.